Navigation Links
ActiGraph Announces Heart Rate Variability Measurement Support
Date:1/28/2013

Pensacola, FL (PRWEB) January 28, 2013

ActiGraph, a leading provider of objective patient monitoring solutions for the global research community, announced today that it now supports the collection of heart rate variability measurements with the release of its ActiLife software version 6.5.

ActiGraph’s newest generation of wireless activity monitoring devices can now be paired with a compatible wireless heart rate monitor to deliver heart rate RR intervals in addition to beats per minute and objective physical activity and sleep/wake measurements such as energy expenditure, activity intensity, steps taken, amount of sleep and body position. Heart rate RR intervals, which are the intervals of time that elapse between the R-waves (peaks) of successive heartbeats, can be used to determine how the variation between consecutive heartbeats changes over time. Heart rate variability is widely regarded as a strong predictor of survival after heart attack and provides valuable insight on nervous system activity and cardiovascular health.

“Many of our clients are involved in research studies and clinical trials involving cardiovascular health and related diseases, so the ability to capture and synchronize heart rate RR intervals with objective physical activity and sleep/wake data is of tremendous value,” said John Schneider, Senior Vice President of Research and Development at ActiGraph. “Heart rate variability measurements add an exciting new dimension to traditional actigraphy data, and we’ve integrated this capability into our existing solution with minimal added cost or burden to the research team and study subjects.”

About ActiGraph
ActiGraph’s extensively validated suite of hardware and software products are widely used by prominent scientific and academic organizations in more than 65 countries in research studies and clinical trials involving physical activity, energy expenditure, and sleep/wake behavior and their relationships to a wide range of health conditions including obesity, diabetes, cancer, cardiovascular disease and sleep disorders. ActiGraph monitoring solutions have delivered objective activity and sleep data to many high profile population studies including the National Health and Nutrition Examination Survey (NHANES), the European Youth Health Study, the U.K. Millennium Cohort Study and the Women’s Health Initiative.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10362395.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ActiGraph Launches ActiLife Mobile App
2. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
3. Carolina Conceptions Announces the Delivery of their First Egg Freeze Pregnancy
4. PhaseRx Announces Technology Evaluation Agreement with Monsanto
5. Taylor-Wharton Announces Release of New Toro Line of Animal Artificial Insemination Products
6. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
7. Oramed Pharmaceuticals Announces Reverse Stock Split
8. Kenrico Announces Records of Patents for 2012 and Financial Targets for 2013
9. Cato Research and Cato BioVentures Announces the Opening of Houston, Texas, Office
10. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
11. NSG Announces New Quartz Micro Flow Channel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Benchworks ... Science Chief Executive Officer Forum on March 23-24 in San Diego. The event ... device and diagnostic industries. , Benchworks Vice President Christian Meyer will also participate ...
Breaking Biology Technology:
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):